Evidence map›Paper›PMID 39887900›Full record

ArticlePharmacology research & perspectives2025

Assessment of Potential Drug-Drug Interactions for Novel Oral Melanocortin-1 Receptor Agonist Dersimelagon.

Akihito Ogasawara, Ryosuke Ide, Shinsuke Inoue, Minoru Tsuda, Renli Teng

Abstract readClinical Trial, Phase IMulticenter Study
In one paragraph

Article in Pharmacology research & perspectives, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Akihito OgasawaraMitsubishi Tanabe Pharma Corporation, Tokyo, Japan.ORCID https://orcid.org/0000-0002-1652-1711
Ryosuke IdeMitsubishi Tanabe Pharma Corporation, Tokyo, Japan.
Shinsuke InoueMitsubishi Tanabe Pharma Corporation, Tokyo, Japan.
Minoru TsudaMitsubishi Tanabe Pharma Corporation, Tokyo, Japan.
Renli TengCareCeutics LLC, Berwyn, Pennsylvania, USA.

Funding

Mitsubishi Tanabe Pharma Corporation
6 · The paper itself

Abstract

Dersimelagon is a novel investigational orally administered selective agonist of the melanocortin-1 receptor. The drug-drug interaction (DDI) potential of dersimelagon was investigated in both nonclinical (in vitro) and clinical studies. The in vitro inhibition of CYP/UGT isoforms and efflux/uptake transporters by dersimelagon was assessed. The impact of 300-mg dersimelagon on the pharmacokinetics (PK) of substrate drugs and the effect of co-administering verapamil on 100-mg dersimelagon PK (as substrate drug) were investigated in healthy participants in a Phase 1 study. DDIs were assessed based on ratios of C

Indexed as

Receptor, Melanocortin, Type 1Administration, OralAdultArea Under CurveAtorvastatinATP Binding Cassette Transporter, Subfamily G, Member 2Drug InteractionsDrugs, InvestigationalFemaleHealthy VolunteersHumansMaleMiddle AgedRosuvastatin CalciumVerapamilYoung AdultAtorvastatinATP Binding Cassette Transporter, Subfamily G, Member 2Drugs, InvestigationalReceptor, Melanocortin, Type 1Rosuvastatin CalciumVerapamil

Identifiers

PMID39887900
PMCPMC11783400

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.